SCHEMBL30920655

SCHEMBL30920655

CCc1cc2cc(CNC(=O)C3(C)CC3)[nH]c2cc1OC

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 7/20 0.41
▸ MTNR1B P49286 6/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ RAB9A P51151 2/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ ALDH1A1 P00352 7/20 0.34
▸ KDM4E B2RXH2 4/20 0.34
▸ HPGD P15428 3/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ PKM P14618 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27247432 1.00 MTNR1A (0.41) MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1
SCHEMBL30920207 0.86 RAB9A (0.41) MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1
SCHEMBL30920360 0.86 SMN1; SMN2 (0.46) MTNR1AMTNR1BSMN1; SMN2RAB9AGAA
SCHEMBL30920782 0.86 SMN1; SMN2 (0.40) MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1
SCHEMBL27246773 0.86 SMN1; SMN2 (0.40) MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1
SCHEMBL27246962 0.86 RAB9A (0.41) MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1
SCHEMBL27247882 0.86 SMN1; SMN2 (0.46) MTNR1AMTNR1BSMN1; SMN2RAB9AGAA
SCHEMBL30920136 0.85 RAB9A (0.38) MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1
SCHEMBL27247588 0.85 RAB9A (0.38) MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1
SCHEMBL30920664 0.84 SMN1; SMN2 (0.39) MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601635-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2025-08-20 — — EP disclosed
Send feedback